Laura Joszt, MA

Secukinumab 150 mg improves signs and symptoms of patients with nonradiographic axial spondyloarthritis, according to results of the PREVENT trial published in Arthritis & Rheumatology.

A new study of patients with rheumatoid arthritis (RA) in Korea has shown that only about half of patients with RA who attained clinical remission were also in imaging remission.

Patients with connective tissue diseases are at greater risk for severe coronavirus disease 2019 (COVID-19) than patients with chronic inflammatory arthritis.

The risk of orthopedic surgery has declined for patients with rheumatoid arthritis (RA) over the course of decades, but the same trend has not occurred for patients with psoriatic arthritis.

Most studies have evaluated PsA-associated fatigue in western populations. A new study has highlighted that PsA-associated fatigue is also prevalent in an Asian population and correlates with disease activity, impact, and chronicity.

A new study in PLOS ONE has highlighted the broad impact fatigue can have on patients with rheumatoid arthritis (RA), psoriatic arthritis, and axial spondyloarthritis.

In the primary analysis of a phase 3 study, ruxolitinib reduced spleen length and symptoms in patients with myelofibrosis, according to results published in British Journal of Haemotology.

Just like in clinical trials, a real-world analysis of patients with psoriatic arthritis who were treated with secukinumab achieved minimal disease activity, as well as other improvements.

Despite concerns, legislation to cap out-of-pocket payments for specialty drugs has not been shown to shift costs to health plans, thereby increasing insurance premiums, according to a study published in New England Journal of Medicine.

The coronavirus disease 2019 (COVID-19) vaccines that are leading the pack are utilizing a new vaccine technology that has never been approved for human use by the FDA. As a result, there are a lot of unknowns.

Patients with rheumatoid arthritis (RA) have a higher risk of cardiovascular disease (CVD), because inflammation plays a pivotal role in the development of CVD. However, there is a need for greater improvement of CVD risk prevention.

During the coronavirus disease 2019 (COVID-19) pandemic, clinics have closed to varying degrees. As clinics look to reopen or welcome back patients after a COVID-19 infection, the American College of Rheumatology (ACR) has released advice on strategies for reopening practices as the pandemic continues.

Patients with myeloproliferative neoplasms (MPNs) have high disease burden, and management of their disease can vary widely to include watchful waiting, phlebotomy, or drug therapy.

Patients who have both skin and joint symptoms with psoriatic arthritis have greater disease burden and worse quality of life compared with patients who have joint-only involvement.

The race for a coronavirus disease 2019 (COVID-19) vaccine is one of the most urgent public health challenges, with multiple vaccine candidates entering phase 3 trials and case counts around the world steadily climbing. MJH Life Sciences™ will host a free webinar with the top minds in infectious disease, virology, and vaccinology to discuss the latest trial information on vaccines.

In children with inflammatory rheumatic diseases, tocilizumab can cause serious adverse events (AEs), with children who were younger at disease onset and at time of tocilizumab initiation especially affected.

Transferring from pediatric to adult care can result in difficulties for patients with childhood-onset systemic lupus erythematosus.

In 2 studies of secukinumab use in real-world settings, researchers identified the usefulness of dose escalation in patients with psoriatic arthritis (PsA), as well as the safety, retention rate, and factors associated with drug survival among patients with PsA and ankylosing spondyloarthritis.

Umbilical cord blood provides a readily available source of stem cells to provide better access to hematopoietic stem cell transplantation to safely and effectively treat various noncancerous genetic disorders in children.

Comorbidities are common in patients with rheumatoid arthritis, and the presence of comorbidities reduces the chance of remission and is associated with worse functional status and disease activity measures.

Two experimental vaccines, one from AstraZeneca and the other from CanSino Biologics, have shown promising results against coronavirus disease 2019 (COVID-19) in a phase 1/2 trial and a phase 2 trial. Results for both were published in The Lancet.

Psoriatic arthritis and psoriasis have high economic burdens and the total annual costs were similar between the 2 diseases, but the combination of both yielded the highest costs, according to an abstract published at the European League Against Rheumatism annual meeting.

Promoting engagement in physical activity in early rheumatoid arthritis (RA) can provide small benefits, according to results from a proof of concept study published in Musculoskeletal Care.

Research identified a new type of cell that is in the blood during the period before a rheumatoid arthritis flare and may be used to predict a flare in the weeks before one occurs, according to research published in New England Journal of Medicine.

Although early diagnosis of axial spondyloarthritis is crucial for patients to receive timely access to care and effective treatment, these patients experience a diagnostic delay of more than 7 years, on average.

Using mindfulness meditation apps may provide an effective way to self-manage and reduce depression and anxiety in patients with myeloproliferative neoplasm (MPNs).

Two abstracts presented at the European Hematology Association's annual meeting evaluated the frequency of myeloid malignancies in patients with autoimmune disease and the impact autoimmune diseases have on patients with sickle cell disease.

A new oral therapy approved by the FDA will provide patients with myelodysplastic syndromes, who typically visit a health care facility for intravenous treatment, with an oral at-home option that can be beneficial during the coronavirus pandemic.

Treatment options for psoriatic arthritis and axial spondyloarthritis are increasing, and with studies already identifying response predictors for tumor necrosis factor inhibitors, there is a need to predict response to the interleukin-17A inhibitor secukinumab.

Patients with systemic lupus erythematosus (SLE) may consider hydroxychloroquine essential to their treatment, but after the drug was identified as a potential therapy for coronavirus disease 2019 (COVID-19), patients with SLE experienced reduced access to the treatment, which could increase the risk of SLE flare.